Press Release
Waltham, MA – February 28, 2007–
HyperMed, Inc., the leader in hyperspectral medical imaging, today
announced the addition of Douglas Lind, MD and Bruce Ryan, PhD
to the HyperMed Board of Directors, joining founders Jenny Freeman,
M.D. and Richard Lifsitz and independent directors Alex Denner,
PhD and Michael Goldblatt, PhD, JD. David Wetherell, Founder and
Managing Partner at Greenwich Biotech Partners will serve as a
board observer.
HyperMed’s OxyVu product provides clinicians with the first
FDA-cleared medical hyperspectral system to non-invasively and
quantitatively assess tissue oxygenation in patients with diabetes
and peripheral vascular disease.
Douglas D. Lind, M.D. is Managing Partner at Greenwich Biotech
Partners, a Greenwich, CT based private equity fund focused on
financing healthcare innovation. He is a former practicing physician
and has more than 20 years experience in a variety of life science
related professions, including serving as senior biotechnology
equity research analyst at Morgan Stanley.
Bruce Ryan, PhD has more than 30 years senior management experience
in sales and marketing positions with International Business Machines
and Digital Equipment Corporation. Dr. Ryan is also a co-founder
of FolderWave, one of the first Web-based application companies
providing complete, complex and high-volume processes over the
Internet as a service.
Dr. Jenny Freeman, President and CEO of HyperMed, commented "Doug
and Bruce bring additional medical and business expertise to the
HyperMed Board. We are excited about their involvement during
this exciting growth phase in the Company’s history.”
HyperMed’s flagship diagnostic device, OxyVu, received
U.S. Food and Drug Administration (FDA) clearance in November,
2006. OxyVu provides clinicians to non-invasively and quantitatively
assess tissue oxygenation in patients with diabetes and peripheral
arterial disease.
HyperMed believes that the better assessment of tissue oxygenation
with OxyVu will lead to improved health outcomes for people suffering
from these diseases, significantly reducing amputations among
these populations.
Medical professionals that that will use HyperMed’s OxyVu
to benefit their patients include vascular surgeons, foot and
ankle surgeons, endocrinologists, orthopedists and wound healing
professionals.
About HyperMed, Inc.
HyperMed, based in Waltham, MA, is the leader in applying hyperspectral
analysis to medical applications. Having been presented at numerous
national and international meetings including the American Diabetes
Association, the American Heart Association, American Association
for the Surgery of Trauma, and the World Congress of Cardiothoracic
Surgery and published in numerous journals, including The Lancet,
The Journal of Trauma and Microvascular Complications
HyperMed’s OxyVu technology is now commercially available
to address diabetic foot ulcers and peripheral arterial disease.
For more information about HyperMed, Inc, and the OxyVu System
please visit website www.hypermed-inc.com.
About Greenwich Biotech Partners
Greenwich Biotech Partners is a Greenwich, CT-based private equity
firm focused on financing innovation in the life sciences. The
firm was founded in early 2005 by David S. Wetherell, founder
and former CEO of CMGI and innovator in the technology and Internet
industries. GBPs’ mission is to improve the human condition
by investing its partner’s capital in the most promising
early- to mid-stage life science companies. For further information
about GBP please visit website www.greenwichbiotech.com.
Press Contacts:
HyperMed, Inc.
Richard Lifsitz
SVP, Corporate Development
781-487-5760
rlifsitz@hypermed-inc.com
Greenwich Biotech Partners
Douglas D. Lind, M.D.
Managing Partner
(203) 769-2348
dlind@gbpcapital.com
www.greenwichbiotech.com
|
